Concepedia

Melissa K. Bennett

MK

Statistics

Publications

3

Citations

81

H-Index

3

Active since

2010

Affiliations

The University of Adelaide(Current)

South Australia Pathology

University of South Australia

Centre for Cancer Biology

Melissa K. Bennett is an author at The University of Adelaide specializing in proteasome inhibitor therapy, pharmacology, and proteasome inhibitors.

ORCID

Publications per year

2010–2021

3

Publications

3

Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress

Craig T. Wallington‐Beddoe, Melissa K. Bennett, Kate Vandyke et al. · Oncotarget · 2017 · 44 citations · Full text

, , +16

Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).

Ravi Vij, David S. Siegel, J. L. Kaufman et al. · Journal of Clinical Oncology · 2010 · 21 citations

, , +15

Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition

Melissa K. Bennett, Manjun Li, Melinda N. Tea et al. · Neoplasia · 2021 · 16 citations · Full text

, , +16

1–3 of 3